Challenge

A biotech company needed support with an active partnering process with several major pharma companies.

Solution

The lead partner had set out aggressive timelines, another was validating the technology in-house, a third was assessing confidential clinical data and a fourth was entering confidentiality.

To secure maximum negotiating leverage, we supported the company with robust valuation models and key lines of argument and rebuttal to be used in term-sheet discussions and subsequent negotiations.